Thermo Fisher Scientific Inc. has launched a new Cell Therapy Collaboration Centre Programme in Singapore to accelerate cell therapy development across the Asia Pacific region. The new centre will serve as the Asia Pacific hub.

The new portfolio of integrated solutions and services will support cell and gene therapy developers from clinical research to commercial manufacturing. 

The programme was officially launched in October, 2022 at the Cell & Gene Therapy Expert Forum Event with over 50 leading developers and thought leaders across the Asia Pacific region. This collaboration programme will allow cell therapy innovators to accelerate the accessibility of potentially curative therapies to patients, from process development to technology transfer and scalability.

The programme offers multiple opportunities to researchers and developers as in, 'access to state-of-the-art Thermo Fisher technologies, protocol and process optimization, product-specific regulatory support to facilitate and expedite clinical translation. Furthermore, the support is extended to product and process scale-up to supply chain readiness and de-risking, as cell therapy programmes advance to commercialisation.

“Being a part of Thermo Fisher’s collaboration programme has helped us to evaluate the potential of utilising automated, closed cell therapy solutions to develop a novel process of manufacturing cell therapies on the OmniCAR platform using non-viral methods,” said Rebecca Lim, senior vice president of scientific affairs, Prescient Technologies.